DK0567566T3 - Fremgangsmåder til behandling af tumornekrosefaktormedierede sygdomme - Google Patents

Fremgangsmåder til behandling af tumornekrosefaktormedierede sygdomme

Info

Publication number
DK0567566T3
DK0567566T3 DK92904429T DK92904429T DK0567566T3 DK 0567566 T3 DK0567566 T3 DK 0567566T3 DK 92904429 T DK92904429 T DK 92904429T DK 92904429 T DK92904429 T DK 92904429T DK 0567566 T3 DK0567566 T3 DK 0567566T3
Authority
DK
Denmark
Prior art keywords
tnf inhibitor
methods
40kda
mediated diseases
treatment
Prior art date
Application number
DK92904429T
Other languages
English (en)
Other versions
DK0567566T4 (da
Inventor
Robert C Thompson
David F Carmichael
Christopher G Smith
Deborah Russell
Tadahiko Kohno
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=24584497&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK0567566(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of DK0567566T3 publication Critical patent/DK0567566T3/da
Application granted granted Critical
Publication of DK0567566T4 publication Critical patent/DK0567566T4/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7151—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for tumor necrosis factor [TNF], for lymphotoxin [LT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Biophysics (AREA)
  • Cardiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DK92904429T 1991-01-18 1992-01-17 Fremgangsmåder til behandling af tumornekrosefaktor-medierede sygdomme DK0567566T4 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US64434591A 1991-01-18 1991-01-18
PCT/US1992/000432 WO1992013095A1 (en) 1991-01-18 1992-01-17 Methods for treating tumor necrosis factor mediated diseases

Publications (2)

Publication Number Publication Date
DK0567566T3 true DK0567566T3 (da) 2000-07-31
DK0567566T4 DK0567566T4 (da) 2007-10-22

Family

ID=24584497

Family Applications (1)

Application Number Title Priority Date Filing Date
DK92904429T DK0567566T4 (da) 1991-01-18 1992-01-17 Fremgangsmåder til behandling af tumornekrosefaktor-medierede sygdomme

Country Status (15)

Country Link
EP (1) EP0567566B2 (da)
JP (2) JP2864434B2 (da)
KR (1) KR100234520B1 (da)
AT (1) ATE190629T1 (da)
AU (2) AU1235692A (da)
CA (1) CA2100329C (da)
DE (1) DE69230789T3 (da)
DK (1) DK0567566T4 (da)
ES (1) ES2145744T5 (da)
GE (1) GEP20002142B (da)
GR (1) GR3033327T3 (da)
NO (1) NO316310B1 (da)
RU (1) RU2166955C2 (da)
SG (1) SG63617A1 (da)
WO (1) WO1992013095A1 (da)

Families Citing this family (76)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL98078A0 (en) * 1991-05-07 1992-06-21 Yeda Res & Dev Pharmaceutical compositions comprising an anticytokyne
US5512544A (en) * 1987-09-13 1996-04-30 Yeda Research And Development Co. Ltd. Pharmaceutical compositions comprising an anticytokine
US7264944B1 (en) 1989-04-21 2007-09-04 Amgen Inc. TNF receptors, TNF binding proteins and DNAs coding for them
DK0393438T3 (da) 1989-04-21 2005-05-30 Amgen Inc TNF-receptor, TNF-bindende proteiner og DNAér, der koder herfor
US6221675B1 (en) 1989-04-21 2001-04-24 Amgen, Inc. TNF receptors, TNF binding proteins and DNAs coding for them
US6143866A (en) * 1989-07-18 2000-11-07 Amgen, Inc. Tumor necrosis factor (TNF) inhibitor and method for obtaining the same
IL95031A (en) 1989-07-18 2007-03-08 Amgen Inc A method of producing a recombinant human necrotic factor absorber
EP1132471A3 (de) 1989-09-12 2001-11-28 F. Hoffmann-La Roche Ag TNF-bindende Proteine
US6284471B1 (en) 1991-03-18 2001-09-04 New York University Medical Center Anti-TNFa antibodies and assays employing anti-TNFa antibodies
US5656272A (en) * 1991-03-18 1997-08-12 New York University Medical Center Methods of treating TNF-α-mediated Crohn's disease using chimeric anti-TNF antibodies
US6277969B1 (en) 1991-03-18 2001-08-21 New York University Anti-TNF antibodies and peptides of human tumor necrosis factor
US5698195A (en) * 1991-03-18 1997-12-16 New York University Medical Center Methods of treating rheumatoid arthritis using chimeric anti-TNF antibodies
US7192584B2 (en) 1991-03-18 2007-03-20 Centocor, Inc. Methods of treating psoriasis with anti-TNF antibodies
DE69230862T2 (de) * 1991-10-15 2000-12-14 Michael F. Mullarkey Rezeptoren zur Behandlung von Entzündungen vom verzögerten Typ
DK0639079T3 (da) * 1992-04-30 2000-06-13 Amgen Inc Fremgangsmåder til behandling af interleukin-1- og tumornekrosefaktor-medierede sygdomme
CA2123593C (en) * 1992-09-15 2000-03-14 Craig A. Smith Method of treating tnf-dependent inflammation using tumor necrosis factor antagonists
US5457129A (en) * 1993-05-17 1995-10-10 Research Development Foundation Inhibition of nitric oxide production by retinoic acid
US5446090A (en) 1993-11-12 1995-08-29 Shearwater Polymers, Inc. Isolatable, water soluble, and hydrolytically stable active sulfones of poly(ethylene glycol) and related polymers for modification of surfaces and molecules
CA2139385C (en) * 1994-02-04 2001-12-25 Gottfried Alber Products containing g-csf and tnf binding protein
US5629384A (en) * 1994-05-17 1997-05-13 Consiglio Nazionale Delle Ricerche Polymers of N-acryloylmorpholine activated at one end and conjugates with bioactive materials and surfaces
US5824784A (en) 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
WO1997003686A1 (en) * 1995-07-14 1997-02-06 Applied Research Systems Tnf receptor and steroid hormone in a combined therapy
US7012060B1 (en) 1995-07-14 2006-03-14 Applied Research Systems Ars Holding N.V. TNF receptor and steroid hormone in a combined therapy
TW555765B (en) 1996-07-09 2003-10-01 Amgen Inc Low molecular weight soluble tumor necrosis factor type-I and type-II proteins
ES2312179T3 (es) 1996-12-06 2009-02-16 Amgen Inc. Terapia combinada que utiliza un inhibidor del il-1 para el tratamiento de enfermedades mediadas por el il-1.
AU5696198A (en) 1996-12-06 1998-06-29 Amgen, Inc. Combination therapy using a tnf binding protein for treating tnf-mediated diseases
EP1028626A4 (en) * 1997-11-07 2001-05-16 Uab Research Foundation METHOD FOR INCREASING GENE EXPRESSION
DE69914932T2 (de) * 1998-10-20 2004-12-09 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw. Verwendung eines zytokine-produzierenden lactococcus stammes zur behandlung von kolitis
US20040220103A1 (en) 1999-04-19 2004-11-04 Immunex Corporation Soluble tumor necrosis factor receptor treatment of medical disorders
US6808902B1 (en) 1999-11-12 2004-10-26 Amgen Inc. Process for correction of a disulfide misfold in IL-1Ra Fc fusion molecules
AU4541101A (en) 2000-03-02 2001-09-12 Xencor Inc Design and discovery of protein based tnf-alpha variants for the treatment of tnf-alpha related disorders
UA81743C2 (uk) 2000-08-07 2008-02-11 Центокор, Инк. МОНОКЛОНАЛЬНЕ АНТИТІЛО ЛЮДИНИ, ЩО СПЕЦИФІЧНО ЗВ'ЯЗУЄТЬСЯ З ФАКТОРОМ НЕКРОЗУ ПУХЛИН АЛЬФА (ФНПα), ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ, ЩО ЙОГО МІСТИТЬ, ТА СПОСІБ ЛІКУВАННЯ РЕВМАТОЇДНОГО АРТРИТУ
TR201809008T4 (tr) 2001-06-26 2018-07-23 Amgen Fremont Inc Opgl ye karşi antikorlar.
TWI327597B (en) 2001-08-01 2010-07-21 Centocor Inc Anti-tnf antibodies, compositions, methods and uses
BR0309095A (pt) 2002-04-10 2005-02-09 Applied Research Systems Uso de osteoprotegerina para o tratamento e/ou prevenção de doença fibrótica
US7585840B2 (en) 2002-04-10 2009-09-08 Merck Serono S.A. Use of osteoprotegerin for the treatment and/or prevention of fibrotic disease
US9028822B2 (en) 2002-06-28 2015-05-12 Domantis Limited Antagonists against TNFR1 and methods of use therefor
CA2500577C (en) 2002-10-08 2013-12-17 Charles A. Dinarello The use of cytokine able to bind il-18bp and of inhibiting the activity of a second cytokine
US7892563B2 (en) 2003-05-20 2011-02-22 Wyeth Holdings Corporation Methods for treatment of severe acute respiratory syndrome (SARS)
US7482376B2 (en) 2003-07-03 2009-01-27 3-Dimensional Pharmaceuticals, Inc. Conjugated complement cascade inhibitors
IL161672A0 (en) 2004-04-29 2004-09-27 Yeda Res & Dev Compositions and methods for therapy of chemotherapy-induced neuropathy
IL161673A0 (en) 2004-04-29 2004-09-27 Applied Research Systems Compositions and methods for therapy of chemotherapy-induced neuropathy
JP2008539194A (ja) 2005-04-26 2008-11-13 ラボラトワール セローノ ソシエテ アノニム 癌および／または関節炎の新たな治療および／または予防
PL1885753T3 (pl) 2005-06-03 2011-12-30 Ares Trading Sa Wytwarzanie rekombinowanego białka wiążącego IL-18
PT1891088E (pt) 2005-06-10 2011-12-19 Ares Trading Sa Processo para a purificação da proteína de ligação il-18
BRPI0613042A2 (pt) 2005-07-15 2010-12-14 Serono Lab inibidores de jnk para o tratamento de endometriose
KR20080044836A (ko) 2005-07-15 2008-05-21 라보라뚜와르 세로노 에스. 에이. 자궁내막증 치료용 ｊｎｋ 억제제
HUE038947T2 (hu) 2005-08-26 2018-12-28 Ares Trading Sa Eljárás glikozilált béta-interferon elõállítására
US8178083B2 (en) 2005-09-01 2012-05-15 Ares Trading, S.A. Treatment of optic neuritis
UA96926C2 (ru) 2005-10-31 2011-12-26 Мерк Сероно Са Применение sdf-1 для лечения и/или профилактики неврологических заболеваний
US8795668B2 (en) * 2005-12-23 2014-08-05 The Regents Of The University Of Michigan Methods for treating pulmonary fibrosis
IL173104A0 (en) 2006-01-12 2006-06-11 Yeda Res & Dev Siva and ubiquintination
AU2007253254B2 (en) 2006-05-24 2013-01-17 Merck Serono Sa Cladribine regimen for treating multiple sclerosis
US7833527B2 (en) 2006-10-02 2010-11-16 Amgen Inc. Methods of treating psoriasis using IL-17 Receptor A antibodies
EP2121931B1 (en) 2007-01-26 2011-05-11 Merck Serono S.A. Purification of fc-tact fusion proteins using the oilbody technology
AU2008314689A1 (en) 2007-10-22 2009-04-30 Merck Serono S.A. Method for purifying an Fc-containing protein
US8415291B2 (en) 2008-10-31 2013-04-09 Centocor Ortho Biotech Inc. Anti-TNF alpha fibronectin type III domain based scaffold compositions, methods and uses
CA2757114C (en) 2009-03-30 2019-05-21 Universite De Lausanne Preparation of isolated agonist anti-edar monoclonal antibodies
TW201117824A (en) 2009-10-12 2011-06-01 Amgen Inc Use of IL-17 receptor a antigen binding proteins
MA33989B1 (fr) 2010-01-15 2013-02-01 Kirin Amgen Inc Formulation d'anticorps et régimes thérapeutiques
WO2011145085A2 (en) 2010-05-21 2011-11-24 Procognia (Israel) Ltd Novel antibodies and methods of use for the treatment and diagnosis of cancer
WO2012050985A1 (en) 2010-10-13 2012-04-19 Trustees Of Boston University Inhibitors of late sv40 factor (lsf) as cancer chemotherapeutics
WO2013016220A1 (en) 2011-07-22 2013-01-31 Amgen Inc. Il-17 receptor a is required for il-17c biology
WO2013138101A2 (en) 2012-03-16 2013-09-19 Children's Medical Center Corporation Calmodulin inhibitors for the treatment of ribosomal disorders and ribosomapathies
EP2832856A4 (en) 2012-03-29 2016-01-27 Chugai Pharmaceutical Co Ltd ANTI-LAMP5 ANTIBODIES AND USE THEREOF
AU2014317035B2 (en) 2013-09-05 2020-02-27 Ab2 Bio Sa IL-18 binding protein (IL-18BP) in inflammatory diseases
ES2760002T3 (es) 2014-03-31 2020-05-12 Amgen K A Inc Métodos de tratamiento de la psoriasis de uñas y cuero cabelludo
CN107660150B (zh) 2015-03-05 2023-10-24 Ab2生物股份有限公司 Il-18结合蛋白(il-18bp)和抗体在炎性疾病中
US10465003B2 (en) 2016-02-05 2019-11-05 Janssen Biotech, Inc. Anti-TNF antibodies, compositions, methods and use for the treatment or prevention of type 1 diabetes
AU2017295262B2 (en) 2016-07-13 2023-07-06 Dana-Farber Cancer Institute, Inc. Calmodulin inhibitors, Chk2 inhibitors and RSK inhibitors for the treatment of ribosomal disorders and ribosomapathies
KR20190113858A (ko) 2017-01-30 2019-10-08 얀센 바이오테크 인코포레이티드 활성 건선성 관절염의 치료를 위한 항-tnf 항체, 조성물, 및 방법
MX2019009377A (es) 2017-02-07 2019-12-11 Janssen Biotech Inc Anticuerpos anti-tnf, composiciones y metodos para el tratamiento de la espondilitis anquilosante activa.
AU2020279987A1 (en) 2019-05-23 2021-11-18 Janssen Biotech, Inc. Method of treating inflammatory bowel disease with a combination therapy of antibodies to IL-23 and TNF alpha
US20230173021A1 (en) 2020-05-06 2023-06-08 Ab2 Bio Sa IL-18 Binding Protein (IL-18BP) In Respiratory Diseases
EP3943097A1 (en) 2020-07-24 2022-01-26 AB2 Bio SA Car-t cell therapy
WO2023166206A1 (en) 2022-03-04 2023-09-07 Ab2 Bio Sa Il-18 binding protein (il-18bp) in the treatment of vexas

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1283046C (en) * 1986-05-29 1991-04-16 Nandini Katre Tumor necrosis factor formulation
IL83878A (en) * 1987-09-13 1995-07-31 Yeda Res & Dev Soluble protein corresponding to tnf inhibitory protein its preparation and pharmaceutical compositions containing it
GB8807803D0 (en) * 1988-03-31 1988-05-05 Glaxo Group Ltd Biochemical product
DK0393438T3 (da) * 1989-04-21 2005-05-30 Amgen Inc TNF-receptor, TNF-bindende proteiner og DNAér, der koder herfor
DE3922089A1 (de) * 1989-05-09 1990-12-13 Basf Ag Neue proteine und ihre herstellung
IL95031A (en) * 1989-07-18 2007-03-08 Amgen Inc A method of producing a recombinant human necrotic factor absorber
SG47099A1 (en) * 1991-03-15 1998-03-20 Amgen Boulder Inc Pegylation of polypeptides

Also Published As

Publication number Publication date
EP0567566A1 (en) 1993-11-03
ATE190629T1 (de) 2000-04-15
NO932610D0 (no) 1993-07-19
DE69230789T2 (de) 2000-08-31
ES2145744T3 (es) 2000-07-16
CA2100329A1 (en) 1992-07-19
JPH06506446A (ja) 1994-07-21
AU702466B2 (en) 1999-02-25
ES2145744T5 (es) 2008-02-01
SG63617A1 (en) 1999-03-30
WO1992013095A1 (en) 1992-08-06
JP2864434B2 (ja) 1999-03-03
EP0567566B1 (en) 2000-03-15
DE69230789D1 (de) 2000-04-20
DK0567566T4 (da) 2007-10-22
EP0567566A4 (en) 1994-10-05
JP3210629B2 (ja) 2001-09-17
KR100234520B1 (ko) 1999-12-15
GR3033327T3 (en) 2000-09-29
EP0567566B2 (en) 2007-07-04
GEP20002142B (en) 2000-06-25
AU4228896A (en) 1996-04-18
NO316310B1 (no) 2004-01-12
RU2166955C2 (ru) 2001-05-20
AU1235692A (en) 1992-08-27
JPH11199505A (ja) 1999-07-27
CA2100329C (en) 2009-09-29
NO932610L (no) 1993-09-09
DE69230789T3 (de) 2007-10-31

Similar Documents

Publication Publication Date Title
DK0567566T4 (da) Fremgangsmåder til behandling af tumornekrosefaktor-medierede sygdomme
RU93051522A (ru) Способ лечения и профилактики заболеваний, обусловленных повышением уровня фактора, вызывающего некроз опухолевых клеток
DK0639079T3 (da) Fremgangsmåder til behandling af interleukin-1- og tumornekrosefaktor-medierede sygdomme
DK0942740T3 (da) Kombinationsterapi under anvendelse af et TFN-bindende protein til behandling af TFN-medierede sygdomme
KR950701350A (ko) 부작용 감소와 동시에 인터페론을 이용한 질환의 치료방법 및 조성물(methods and compositions for the treatment of diseases with interferon while reducing side effects)
JP2004518632A5 (da)
DK0512528T3 (da) Farmaceutisk præparat omfattende et cytokin
DE69215722D1 (de) Verstärker zur Ultraschalltherapie von Erkrankungen sowie diesen enthaltende flüssige Arzneimittelzusammensetzungen
DE69433501D1 (de) Oxazole zur behandlung von zytokinvermittelten erkrankungen
EP2002846A3 (en) Combination therapy using an IL-1 inhibitor for treating IL-1 mediated diseases
DK16890D0 (da) Antiviral eller antibakteriel forbindelse og frem gangsmaade til anvendelse heraf
DK2145629T3 (da) Anvendelse af neurotoksinterapi til behandling af urologiske og relaterede sygdomme
DK241287D0 (da) Anvendelse af glutamin til fremstilling af et laegemiddel til behandling af kataboliske forstyrrelser
DK0687184T3 (da) Rekombinante adenoviruser og anvendelse deraf ved genterapi til behandling af øjensygdomme
NO894222D0 (no) Fremgangsmaater for behandling av profylakse av pneumocytis carinii pneumoni og andre sykdommer og forbindelser og formuleringer til anvendelse i nevnte metoder.
ATE341316T1 (de) Kontrolle der wundvernarbung mit calmodulin- inhibitoren oder protein-kinase-c-inhibitoren
NO971453D0 (no) Anvendelse av bradykinin-antagonister for fremstilling av legemidler for behandling av kroniske fibrogenetiske og akutte leversykdommer
DK0859630T3 (da) Kombination af termozolomid og alfa-IFN til behandling af fremskreden cancer
ATE306278T1 (de) Behandlung von knochenleiden mit adrenomedullin
ES2111068T3 (es) Proteina anti-vih, tap 29, a partir de trichosanthes codificada adn y usos terapeuticos de la misma.
ATE109349T1 (de) 3-substituierte-2-oxindolderivate als interleukin-biosynthesehemmer.
MX9606137A (es) Composiciones y metodos para el tratamiento de tumores.
BG101716A (en) 4,4-(DISUBSTITUTED)CYCLOHEXAN-l-OLS MONOMERS AND RELATED COMPOUNDS
EP0321094A3 (en) Treatment of factor viii inhibitors
RU93037460A (ru) Способ лечения псориаза и пузырчатки